Kalodimou G, Jany S, Freudenstein A, Schwarz J, Limpinsel L, Rohde C
Viruses. 2023; 15(5).
PMID: 37243266
PMC: 10222707.
DOI: 10.3390/v15051180.
Al-Mhanna S, Ghazali W, Maqsood A, Mohamed M, Ahmed N, Afolabi H
SAGE Open Med. 2023; 11:20503121231158981.
PMID: 36909796
PMC: 9996076.
DOI: 10.1177/20503121231158981.
Nicolas A, Sannier G, Dube M, Nayrac M, Tauzin A, Painter M
iScience. 2023; 26(1):105904.
PMID: 36594081
PMC: 9797215.
DOI: 10.1016/j.isci.2022.105904.
Abdelhamid M, Almsellati I, Annajar B, Abdulhamid A, Alemam H, Etikar M
PLoS One. 2022; 17(11):e0276425.
PMID: 36327290
PMC: 9632805.
DOI: 10.1371/journal.pone.0276425.
Mak H, Dai T, Tang C
Prod Oper Manag. 2022; .
PMID: 36246547
PMC: 9538244.
DOI: 10.1111/poms.13862.
Vaccination strategies when vaccines are scarce: on conflicts between reducing the burden and avoiding the evolution of escape mutants.
Geoffroy F, Traulsen A, Uecker H
J R Soc Interface. 2022; 19(191):20220045.
PMID: 35765804
PMC: 9240677.
DOI: 10.1098/rsif.2022.0045.
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
Nayrac M, Dube M, Sannier G, Nicolas A, Marchitto L, Tastet O
Cell Rep. 2022; 39(13):111013.
PMID: 35732172
PMC: 9189142.
DOI: 10.1016/j.celrep.2022.111013.
Efficacy versus abundancy: Comparing vaccination schemes.
El Deeb O, Jalloul M
PLoS One. 2022; 17(5):e0267840.
PMID: 35552553
PMC: 9097986.
DOI: 10.1371/journal.pone.0267840.
Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose.
Berec L, Levinsky R, Weiner J, Smid M, Neruda R, Vidnerova P
Sci Rep. 2022; 12(1):7638.
PMID: 35538118
PMC: 9086670.
DOI: 10.1038/s41598-022-11250-4.
The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants.
Kim D, Keskinocak P, Pekgun P, Yildirim I
Sci Rep. 2022; 12(1):7493.
PMID: 35523832
PMC: 9075929.
DOI: 10.1038/s41598-022-11060-8.
Evaluating the effects of second-dose vaccine-delay policies in European countries: A simulation study based on data from Greece.
Barmpounakis P, Demiris N, Kontoyiannis I, Pavlakis G, Sypsa V
PLoS One. 2022; 17(4):e0263977.
PMID: 35446847
PMC: 9022792.
DOI: 10.1371/journal.pone.0263977.
COVID-19 Vaccination, Peltzman Effect and Possible Increase in Highrisk Behaviors: A Growing Concern Related to Risk Compensation and Reduced Compliance to Public Health Protective Measures after Vaccines Rollout.
Falahi S, Mohamadi J, Sayyadi H, Pakzad I, Rashidi A, Naserifar R
Infect Disord Drug Targets. 2022; 22(8):8-12.
PMID: 35440338
DOI: 10.2174/1871526522666220419133849.
Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum.
Kaura A, Trickey A, Shah A, Benedetto U, Glampson B, Mulla A
EClinicalMedicine. 2022; 46:101344.
PMID: 35295900
PMC: 8918854.
DOI: 10.1016/j.eclinm.2022.101344.
Projecting the impact of Covid-19 variants and vaccination strategies in disease transmission using a multilayer network model in Costa Rica.
Garcia Y, Mery G, Vasquez P, Calvo J, Barboza L, Rivas T
Sci Rep. 2022; 12(1):2279.
PMID: 35145180
PMC: 8831570.
DOI: 10.1038/s41598-022-06236-1.
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
Nayrac M, Dube M, Sannier G, Nicolas A, Marchitto L, Tastet O
bioRxiv. 2022; .
PMID: 34981046
PMC: 8722583.
DOI: 10.1101/2021.12.18.473317.
A model predictive control approach to optimally devise a two-dose vaccination rollout: A case study on COVID-19 in Italy.
Parino F, Zino L, Calafiore G, Rizzo A
Int J Robust Nonlinear Control. 2021; .
PMID: 34908815
PMC: 8661761.
DOI: 10.1002/rnc.5728.
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa.
Reddy K, Fitzmaurice K, Scott J, Harling G, Lessells R, Panella C
Nat Commun. 2021; 12(1):6238.
PMID: 34716349
PMC: 8556310.
DOI: 10.1038/s41467-021-26557-5.
The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model.
Catala M, Li X, Prats C, Prieto-Alhambra D
Sci Rep. 2021; 11(1):18812.
PMID: 34552139
PMC: 8458447.
DOI: 10.1038/s41598-021-98216-0.
Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses.
Hill E, Keeling M
J R Soc Interface. 2021; 18(182):20210214.
PMID: 34465208
PMC: 8437233.
DOI: 10.1098/rsif.2021.0214.
Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use.
Ahmed S, Khan S, Imran I, Al Mughairbi F, Sultan Sheikh F, Hussain J
Vaccines (Basel). 2021; 9(8).
PMID: 34451961
PMC: 8402459.
DOI: 10.3390/vaccines9080836.
